When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ALPMY - FibroGen down 6% despite positive roxadustat date in late-stage CKD study
Astellas Pharma Inc. ADR
A Phase 3 clinical trial, HIMALAYAS, evaluating FibroGen's (FGEN-6%) roxadustat in chronic kidney disease (CKD) patients who recently initiated dialysis met both primary endpoints. The data were presented at the American Society of Nephrology Kidney Week in Washington, DC.
More news on: FibroGen, Inc., AstraZeneca PLC, Astellas Pharma Inc., Healthcare stocks news, Stocks on the move,